Medicare should continue to pay average sales price plus 6% for most separately payable Part B drugs, but cap ASP inflation, AHA told the Medicare Payment Advisory Commission in comments submitted today. 

At its January meeting, MedPAC discussed modifying the ASP add-on payment to the lesser of 6%, 3% plus $24, or $220 per drug per day; and using reference pricing to address high prices and price growth for new and existing drugs with therapeutic alternatives. AHA expressed concern that both proposals would shift responsibility for rapid growth in drug prices from drug makers to hospitals and patients.

Among other comments, AHA recommended Medicare permanently extend certain telehealth flexibilities used to expand access to care during the COVID-19 pandemic and reconsider certain other policy options that run contrary to what these permanent extensions would accomplish.
 

Related News Articles

Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
Senate Finance Committee Chair Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, released a white paper May 17 outlining policy concepts regarding pay…
Headline
The RAND Corporation May 13 released its latest hospital pricing report, which focuses on prices paid for care at the hospital and service-line level. In…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…